<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
<journal-id journal-id-type="publisher-id">hmg</journal-id>
<journal-id journal-id-type="hwp">hmg</journal-id>
<journal-title-group>
<journal-title>Human Molecular Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-6906</issn>
<issn pub-type="epub">1460-2083</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26908603</article-id>
<article-id pub-id-type="pmc">4986327</article-id>
<article-id pub-id-type="doi">10.1093/hmg/ddw039</article-id>
<article-id pub-id-type="publisher-id">ddw039</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>NF1</italic> germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Toonen</surname>
<given-names>Joseph A.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anastasaki</surname>
<given-names>Corina</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smithson</surname>
<given-names>Laura J.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gianino</surname>
<given-names>Scott M.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Kairong</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kesterson</surname>
<given-names>Robert A.</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutmann</surname>
<given-names>David H.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="af1"><sup>1</sup>Department of Neurology, Washington University School of Medicine, PO Box 8111, 660 S. Euclid Avenue, St. Louis, MO 63110, USA and</aff>
<aff id="af2"><sup>2</sup>Department of Genetics, University of Alabama, Birmingham, AL 35233, USA</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">*To whom correspondence should be addressed. Tel: +314 362 7379; Fax: +314 362 2388; Email: <email>gutmannd@neuro.wustl.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>01</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>25</volume>
<issue>9</issue>
<fpage>1703</fpage>
<lpage>1713</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="ddw039.pdf"></self-uri>
<abstract>
<p>Neurofibromatosis type 1 (NF1) is a common neurogenetic condition characterized by significant clinical heterogeneity. A major barrier to developing precision medicine approaches for NF1 is an incomplete understanding of the factors that underlie its inherent variability. To determine the impact of the germline <italic>NF1</italic> gene mutation on the optic gliomas frequently encountered in children with NF1, we developed genetically engineered mice harboring two representative NF1-patient-derived <italic>Nf1</italic> gene mutations (c.2542G&gt;C;p.G848R and c.2041C&gt;T;p.R681X). We found that each germline <italic>Nf1</italic> gene mutation resulted in different levels of neurofibromin expression. Importantly, only R681X<sup>CKO</sup> but not G848R<sup>CKO</sup>, mice develop optic gliomas with increased optic nerve volumes, glial fibrillary acid protein immunoreactivity, proliferation and retinal ganglion cell death, similar to <italic>Nf1</italic> conditional knockout mice harboring a neomycin insertion (neo) as the germline <italic>Nf1</italic> gene mutation. These differences in optic glioma phenotypes reflect both cell-autonomous and stromal effects of the germline <italic>Nf1</italic> gene mutation. In this regard, primary astrocytes harboring the R681X germline <italic>Nf1</italic> gene mutation exhibit increased basal astrocyte proliferation (BrdU incorporation) indistinguishable from neo<sup>CKO</sup> astrocytes, whereas astrocytes with the G848R mutation have lower levels of proliferation. Evidence for paracrine effects from the tumor microenvironment were revealed when R681X<sup>CKO</sup> mice were compared with conventional neo<sup>CKO</sup> mice. Relative to neo<sup>CKO</sup> mice, the optic gliomas from R681X<sup>CKO</sup> mice had more microglia infiltration and JNK<sup>Thr183/Tyr185</sup> activation, microglia-produced Ccl5, and glial AKT<sup>Thr308</sup> activation. Collectively, these studies establish that the germline <italic>Nf1</italic> gene mutation is a major determinant of optic glioma development and growth through by both tumor cell-intrinsic and stromal effects.</p>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>Vision Sciences</funding-source>
<award-id>5-T32-EY13360</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>Neuroscience</funding-source>
<award-id>5-T32-NS007205-33</award-id>
</award-group>
<award-group id="funding-3">
<funding-source>National Cancer Institute <named-content content-type="funder-id">http://dx.doi.org/10.13039/100000054</named-content></funding-source>
<award-id>1R01-CA195692-01</award-id>
</award-group>
<award-group id="funding-4">
<funding-source>Alex's Lemonade Stand Foundation</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="11"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>